Malignant Mastocytosis — Trials

Malignant Mastocytosis — Trials · CancerIndex

Clinical trials

Registered studies

14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 67%
Top sponsor: Cogent Biosciences, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05609942	Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies(AZURE)	terminated	Phase 1	9	Blueprint Medicines CorporationINDUSTRY	7	Apr 10, 2025	clinicaltrials
NCT02415608	Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	terminated	Phase 2	4	Jason Robert GotlibOTHER	1	Sep 20, 2018	clinicaltrials